About Kevin Liu, MD, DPhil
Dr. Liu is an Assistant Professor of Radiation Oncology at Harvard Medical School and the Director of Sarcoma Radiation Oncology at Massachusetts General Hospital. He has a clinical focus on sarcomas and pediatric malignancies. He received his undergraduate degree summa cum laude from Harvard College, his doctorate from the University of Oxford as a Fulbright and Clarendon Scholar, and his medical degree from Harvard Medical School. Dr. Liu completed his residency in radiation oncology at the Harvard Radiation Oncology Program where he served as Chief Resident.
His research focuses on novel treatment strategies for sarcomas, diffuse midline gliomas, high-grade gliomas, and neuroblastomas; improving outcomes after radiation for patients with sarcomas and pediatric patients with cancer; developing treatment paradigms for rare diseases; and closing gaps in healthcare disparities for underrepresented patient populations. His research has been published in The Lancet Oncology, Journal of Clinical Oncology, JAMA Oncology, International Journal of Radiation Oncology • Biology • Physics, and Cancer, and Radiotherapy & Oncology. He also serves as an associate editor for Frontiers in Oncology. Dr. Liu teaches and mentors medical students and residents.
Clinical Interests:
- Chondrosarcoma
- Chordoma
- Ewing Sarcoma
- Osteosarcoma
- Pediatric brain tumors
- Pediatric hematologic malignancies
- Pediatric malignancies
- Pediatric oncology
- Pediatric tumors
- Rhabdomyosarcoma
- Sarcomas
Treats:
- Adult & Pediatrics
Languages:
- Mandarin Chinese
Locations
Mass General Cancer Center: Radiation Oncology
55 Fruit St.
Lunder Building, LL3
Boston, MA 02114
Phone: 617-726-8651
Medical Education
- MD, Harvard Medical School
- Residency, Mass General Hospital
American Board Certifications
- Radiation Oncology, American Board of Radiology
Accepted Insurance Plans
- Blue Cross Blue Shield
- Harvard Pilgrim Health Care
- Medicaid CT
- Medicare ACO
- Tufts Health Plan
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Publications
-
Selected publications:
- Liu KX, Naranjo A, Zhang FF, DuBois SG, Braunstein SE, Voss SD, Khanna G, London WB, Doski JJ, Geiger JD, Kreissman SG, Grupp SA, Diller LR, Park JR, Haas-Kogan DA. Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. J Clin Oncol. 2020 Aug 20;38(24):2741-2752. doi: 10.1200/JCO.19.03316. PMID: 32530765.
- Liu KX, Collins NB, Greenzang KA, Furutani E, Campbell K, Groves A, Mullen EA, Shusterman S, Spidle J, Marcus KJ, Weil BR, Weldon CB, Frazier AL, Janeway KA, O'Neill AF, Mack JW, DuBois SG, Shulman DS. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 Oct;67(10):e28559. doi: 10.1002/pbc.28559. PMID: 32686305.
- Liu KX*, Lamba N*, Hwang WL, Niemierko A, DuBois SG, Haas-Kogan DA. Risk stratification by somatic mutation burden in Ewing sarcoma. Cancer. 2019 Apr 15;125(8):1357-1364. doi: 10.1002/cncr.31919. PMID: 30602061.(*denotes co-first authors)
- Liu KX*, Ioakeim-Ioannidou M*, Susko MS, Rao AD, Yeap BY, Snijders AM, Ladra MM, Vogel J, Zaslowe-Dude C, Marcus KJ, Yock TI, Grassberger C, Braunstein SE, Haas-Kogan DA, Terezakis SA, MacDonald SM. A Multi-institutional Comparative Analysis of Proton and Photon Therapy-Induced Hematologic Toxicity in Patients With Medulloblastoma. Int J Radiat Oncol Biol Phys. 2021 Mar 1;109(3):726-735. doi: 10.1016/j.ijrobp.2020.09.049. Epub 2020 Nov 23. PMID: 33243479.(*denotes co-first authors)
- Liu KX, Chen YH, Kozono D, Mak RH, Boyle PJ, Janeway KA, Mullen EA, Marcus KJ. Phase I/II Study of Stereotactic Body Radiation Therapy for Pulmonary Metastases in Pediatric Patients. Adv Radiat Oncol. 2020 Sep 23;5(6):1267-1273. doi: 10.1016/j.adro.2020.09.004. PMID: 33305087.
- Liu KX, Indelicato DJ, Paulino AC, Looi WS, Catalano PJ, Chintagumpala MM, Gallotto SL, Marcus KJ, Haas-Kogan DA, Tarbell NJ, MacDonald SM, Mahajan A, Yock TI. Multi-institutional Characterization of Outcomes for Pediatric and Young Adult Patients With High-Risk Myxopapillary Ependymoma After Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023 Dec 1;117(5):1174-1180. doi: 10.1016/j.ijrobp.2023.06.2293. Epub 2023 Jul 10. PMID: 37437812.
- Haas-Kogan DA, Aboian MS, Minturn JE, Leary SES, Abdelbaki MS, Goldman S, Elster JD, Kraya A, Lueder MR, Ramakrishnan D, von Reppert M, Liu KX, Rokita JL, Resnick AC, Solomon DA, Phillips JJ, Prados M, Molinaro AM, Waszak SM, Mueller S. Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial. J Clin Oncol. 2024 Feb 1;42(4):441-451. doi: 10.1200/JCO.23.01838. Epub 2023 Nov 17. PMID: 37978951; PMCID: PMC10824388.
- Liu KX, Shaaban SG, Chen JJ, Bagatell R, Lerman BJ, Catalano PJ, DuBois SG, Shusterman S, Ioakeim-Ioannidou M, Yock TI, Shamberger RC, Mattei P, Vu L, Elhalawani H, Dusenbery KE, Vo KT, Huang MS, Friedmann AM, Diller LR, Marcus KJ, MacDonald SM, Terezakis SA, Braunstein SE, Hill-Kayser CE, Haas-Kogan DA. Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field. Radiother Oncol. 2024 Jun 15;198:110384. doi: 10.1016/j.radonc.2024.110384. Epub ahead of print. PMID: 38880415.